

Standalone Statement of Assets and Liabilities as on 31st March, 2022.

Rs. in Lacs

S.No	Particulars	Note No.	As at March 31, 2022	As at March 31, 2021
A	ASSETS			
	Non-Current Assets			
	(a) Property, Plant and equipment	2	354.11	351.80
	(b) Capital Work in Progress		1,903.89	352.98
	(c) Investment Property			
	(d) Other Intangible Assets			
	(e) Financial Assets			
	(i) Investments		-	-
	(ii) Other financial assets	3	8.07	0.84
	(f) Deferred Tax Assets			
	(g) Other Non-Current Assets	4	-	-
	Total non-Current Assets		2,266.07	705.62
	Current Assets			
	(a) Inventories		-	-
	(b) Financial Assets			
	(i) Other Investments		-	-
	(ii) Trade Receivables		-	-
	(iii) Cash and Cash Equivalents	5	11.94	0.27
	(iv) Bank balances other than (iii) above	6	177.38	150.00
	(v) Loans		-	-
	(v) Other Financial assets		-	-
	(c) Current tax assets (Net)		0.83	-
	(d) Other current Assets	7	1,625.76	100.34
	(e) Trade Receivables		-	-
	Total Current Assets		1,815.91	250.62
	TOTAL ASSETS		4,081.98	956.24
B	EQUITY AND LIABILITIES			
	Equity			
	(a) Equity Share Capital	8	1.00	1.00
	(b) Other Equity	9	-7.48	-3.49
	(c) Money Received against Share warrants			
	Total Equity		-6.48	-2.49
	Liabilities			
	Non-Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	10	3,952.25	917.48
	(ii) Other Financial Liabilities	10A	-	-
	(b) Deferred Tax Liabilities			
	(c) Provisions			
	(d) Other Non-Current liabilities			
	Total Non-Current Liabilities		3,952.25	917.48
	Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings			
	(ii) Trade Payables			
	Dues of micro enterprises and small enterprises	11	-	-
	Dues of creditors other than micro enterprises and small enterprises	11	-	-
	(iii) Other Financial Liabilities	12	128.31	36.15
	(b) Provisions			
	(c) Other Current Liabilities	13	7.90	5.10
	Total Current Liabilities		136.21	41.25
	Total Liabilities		4,088.46	958.72
	TOTAL EQUITY & LIABILITIES		4,081.98	956.24

The accompanying notes are an integral part of these financial Statements

0.00

In terms of our report attached

For and on behalf of the Board

For P.Chandrasekar LLP
Chartered Accountants
FRN.: 000580S/S200066

P.Chandrasekar
Partner
Membership No.026037

Place: Bengaluru
Date: 09/05/2022



Sunil L Mundra
Director
DIN:00214304

Sushil Kumar Mundra
Director
DIN:214332

NATURAL BIOGENEX PRIVATE LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: U24239KA2020PTC137602

AUDITED STANDALONE FINANCIAL RESULTS FOR THE YEAR ENDED 31st MARCH,2022

Rs. in Lacs

S.No	Particulars	Note No.	For the Year ended March 31, 2022	For the Year ended March 31, 2021
I	Revenue from Operations	14		
II	Other Income	15	8.08	0.25
III	Total Income (I+II)		8.08	0.25
IV	Expenses:			
	Cost of materials consumed		-	-
	Changes in Inventories of finished goods, work-in-progress and stock in trade		-	-
	Employee benefit expense		-	-
	Finance costs		-	-
	Depreciation and amortisation expense	16	0.20	-
	Other expenses	17	11.87	3.73
	Total Expenses (IV)		12.07	3.73
V	Profit before exceptional items and Tax (III-IV)		-4.00	-3.49
VI	Exceptional items - Income /(Expenses)			
VII	Profit before Tax (V - VI)		-4.00	-3.49
VIII	Tax Expense:			
	1) Current tax			
	2) Tax for earlier			
	3) Deferred tax			
	Total Tax expenses			
IX	Profit for the year (VII-VIII)		-4.00	-3.49
	Other Comprehensive Income			
	A. i) Items that will not be reclassified to profit or loss			
	a) Re-measurement of the defined benefit plan			
	b) Equity instruments through other comprehensive income			
	ii) Income tax relating to items that will not be re-classified to profit or loss			
	B. i) Items that will be reclassified to profit or loss			
	ii) Income tax relating to items that will be re-classified to profit or loss			
X	Total other comprehensive income (A(i-ii)+B(i-ii))			
XI	Total Comprehensive Income (IX+X)		-4.00	-3.49
XII	Earnings Per Equity Share (Nominal value per share Rs.10/-)			
	(a) Basic		-39.96	-34.85
	(b) Diluted		-39.96	-34.85

The accompanying notes are an integral part of these financial statements

In terms of our report attached

For P.Chandrasekar LLP
Chartered Accountants
FRN.: 000580S/S200066

P Chandrasekar
Partner
Membership No.026037

Place: Bengaluru
Date: 09/05/2022



For and on behalf of the Board

(Signature)

Sunil L Mundra
Managing Director
DIN:00214384

(Signature)

Sushil Kumar Mundra
Director
DIN:214332

NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: U24239KA2020PTC137602

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2022

Rs in Lacs

Particulars	For the Year ended March 31,		For the Year ended March 31,	
	2022		2021	
A. Cash flow from operating activities				
Profit before tax		-4.00		-3.49
Adjustments for:				
Depreciation and Amortisation		-		-
Finance Costs (net)		-		-
Profit on sale of Fixed Assets (net)		-		-
Interest Income	-8.08		-0.25	
Bad Debts		-		-
Liability no longer required written back		-		-
Profit on sale of investments		-		-
Re-measurement of the defined benefit plan		-		-
		-8.08		-0.25
Operating profit before working capital changes		-12.07		-3.73
Changes in working capital				
Adjustments for increase / (decrease) in				
Trade and other receivables				
Inventories				
Bank balances other than cash and cash equivalent	-27.38		-150.00	
Other Current Assets	-1,526.25		-100.34	
Other Financial Assets	-7.24		-0.84	
Trade Payable				
Other Liabilities	2.80		5.10	
Provisions				
Other Financial Liabilities	92.16		36.15	
Cash generated from operations		-1,465.91		-209.93
		-1,477.98		-213.66
Taxes paid				
Net cash generated from operating activities		-1,477.98		-213.66
B. Cash flow from investing activities				
Purchase of fixed assets including capital advances and CWIP	-1,553.21		-704.78	
Proceeds from sale of fixed assets				
(Purchase) / Sale of investments				
Investment income				
Interest received	8.08		0.25	
Dividend received		-1,545.13		-704.54
Net cash used in investing activities		-1,545.13		-704.54
C. Cash flow from Financing activities				
Proceeds from issue of Share Capital			1.00	
Proceeds from borrowings	3,034.78		917.48	
Repayment of Long Term loan Borrowings / Advances				
Finance Cost				
Lesae Payment - Including Interest Cost				
Dividend paid				
Dividend Distribution tax paid		3,034.78		918.48
Net cash used in financing activities		3,034.78		918.48
Net (decrease) / increase in cash and cash equivalents (A+B+C)		11.66		0.27
Reconciliation				
Cash and cash equivalents as at beginning of the year		0.27		-
Cash and cash equivalents as at end of the year		11.94		0.27
Net increase / (decrease) in cash and cash equivalents		11.66		0.27

The accompanying notes are an integral part of these financial statements

In terms of our report attached

For and on behalf of the Board

For P.Chandrasekar LLP
Chartered Accountants
FRN.: 000580S/S200066

P.Chandrasekar
Partner
Membership No.026037



Sunil L Mundra
Managing Director
DIN:00214304

Sushil Kumar Mundra
Director
DIN:214332

Place: Bengaluru
Date: 09/05/2022

NATURAL BIOGENEX PRIVATE LIMITED
Statement of Changes in Equity Share Capital and Other Equity for the year ended 31st March 2022

Reserves and Surplus	Share Capital	Securities Premium	Retained earnings	Items of other comprehensive income			Total
				Equity Instruments through other Comprehensive income	Actuarial Gain / Loss	Others (specify)	
Balance at March 31,2020							
share allotment	1.00	-					1.00
Profit for the period			-3.49				-3.49
Payment of Dividend and Dividend Distribution Tax							
Balance at March 31,2021	1.00	-	-3.49	-	-	-	-2.49
Profit for the year			-4.00				-4.00
Additions during the year			-				-
Total comprehensive Income / Expenses for the current year							
Balance at March 31,2022	1.00	-	-7.48	-	-	-	-6.48

The accompanying notes are an integral part of these financial statements

In terms of our report attached

For and on behalf of the Board

For P.Chandrasekar LLP
Chartered Accountants
FRN.: 0005805/5200066



P Chandrasekar
Partner
Membership No.026037

Place: Bengaluru
Date: 09/05/2022


Sunil L Mundra
Director
DIN:00214304


Sushil Kumar Mundra
Director
DIN:214332

NATURAL BIOGENEX PRIVATE LIMITED
Notes forming part of the Financial Statements

NOTE

OTHER INTANGIBLE ASSETS

Particulars	As at March 31, 2022	As at March 31, 2021
Carrying amounts of:		
Software and licenses		
Total		

Particulars	As at March 31, 2022	As at March 31, 2021
Cost or Deemed cost		
Balance at the beginning of the year		
Additions		
Balance at end of the year		

Particulars	As at March 31, 2022	As at March 31, 2021
Accumulated depreciation and impairment		
Balance at the beginning of the year		
Depreciation expenses		
Balance at end of the year		
Carrying amount at the end of year		

NOTE

INVESTMENTS - NON CURRENT

Particulars	As at March 31, 2022	As at March 31, 2021
I. Quoted Investments		
II. Un-quoted Investments		
Investments in the nature equity in subsidiaries		
Investment in equity shares		
Other Investments		
Total aggregate of un-quoted Investments		
Aggregate book value of unquoted investments		
Aggregate market value of quoted investments		

NOTE 3

OTHER FINANCIAL ASSETS - Non Current

Particulars	As at March 31, 2022	As at March 31, 2021
At Amortized Cost		
a) Security Deposit (Unsecured considered good)	0.59	0.59
b) Prepaid Rent deposit		
c) Term Deposit		
d) Dividend from Associate /Subsidiary		
Less: Provision for Doubtful advances		
e) Interest Receivable On Deposits		
Secured, Considered good	7.48	0.25
Unsecured, Considered good		
Doubtful		
Less: Allowance for doubtful debts (Expected Credit Loss)		
f) Other receivable		
Total	8.07	0.84

NOTE 4

OTHER ASSETS - NON CURRENT

Particulars	As at March 31, 2022	As at March 31, 2021
a) Security Deposit		
b) Capital Advances		

Smita



NATURAL BIOGENEX PRIVATE LIMITED
Notes forming part of the Financial Statements

(i) Secured, Considered good		
(ii) Unsecured and Considered good		
(iii) Considered doubtful		
Less: Allowance for doubtful debts (Expected Credit Loss)		
e) Export incentive receivable		
f) Balance with Customs and Central excise / GST authorities		
Total	-	-

NOTE

INVENTORIES

Particulars	As at March 31, 2022	As at March 31, 2021
Lower of Cost or Net realisable value		
a) Raw Materials		-
b) Work-in-Process		-
c) Finished goods		-
d) Stock in trade (acquired for trading)		
e) Stores and spares		
f) Goods in Transit		
Less: Provision for Stock Reserve		
Total		-

NOTE

TRADE RECEIVABLES

Particulars	As at March 31, 2022	As at March 31, 2021
Trade Receivables		
Secured, Considered good		
Unsecured, Considered good		
Doubtful		
Allowance for doubtful debts (Expected Credit Loss)		
	-	-
Current	-	-
Non-current	-	-

The credit period on sale of goods ranges from 0 to 90 days. No interest is charged on trade receivables.

The Company uses available information in the public domain and on its own internal assessment and trading records before accepting any customer.

As at March 31, 2022	Outstanding for following periods from due date of payment				
	Particulars	Less than 6 months	6 months -1 year	1-2 Years	2-3 years
(i) Undisputed Trade receivables – considered good	-	-	-	-	-
(ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-
(iii) Undisputed Trade Receivables – credit impaired	-	-	-	-	-
(iv) Disputed Trade Receivables–considered good	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-

As at March 31, 2021	Outstanding for following periods from due date of payment				
	Particulars	Less than 6 months	6 months -1 year	1-2 Years	2-3 years
(i) Undisputed Trade receivables – considered good	-	-	-	-	-
(ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-
(iii) Undisputed Trade Receivables – credit impaired	-	-	-	-	-
(iv) Disputed Trade Receivables–considered good	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-

NOTE 5

CASH AND CASH EQUIVALENTS



NATURAL BIOGENEX PRIVATE LIMITED
Notes forming part of the Financial Statements

Particulars	As at March 31, 2022	As at March 31, 2021
a) Balances with banks		
(i) In Current account	11.94	0.27
(ii) In Deposit account with original maturity less than 3 Months		
(iii) In EEFC account		
b) Cash on hand		-
c) Cheques, drafts on hand		
Total	11.94	0.27

NOTE 6

OTHER BANK BALANCES

Particulars	As at March 31, 2022	As at March 31, 2021
a) Deposit Accounts		
Term Deposit	175.14	150.00
Margin Money	2.24	
b) Earmarked Balances with banks		
(i) In unpaid Dividend account	-	-
(ii) In margin money accounts for Bank Guarantee issued	-	-
Total	177.38	150.00

NOTE

CURRENT TAX ASSETS

Particulars	As at March 31, 2022	As at March 31, 2021
TDS/TCS Receivable	0.83	-
Total	0.83	-

NOTE 7

OTHER CURRENT ASSETS

Particulars	As at March 31, 2022	As at March 31, 2021
a) Security Deposit		
b) Capital Advances	1,172.52	10.00
c) Advances to Employees		
(i) Secured, Considered good		
(ii) Unsecured and Considered good	0.50	0.42
(iii) Considered doubtful		
Less: Allowance for doubtful debts (Expected Credit Loss)		
e) Export incentive receivable		
f) Balance with Customs and Central excise / GST authorities	74.53	2.68
g) Advance to suppliers		
(i) Secured, Considered good		
(ii) Unsecured and Considered good		32.24
(iii) Considered doubtful		
Less: Allowance for doubtful debts (Expected Credit Loss)		
h) Prepaid Expenses		
i) Preliminary -Pre Operative Expenses	378.21	55.00
j) Other Advances		
Less: Provision for Doubtful advances		
Total	1,625.76	100.34

NOTE 9

OTHER EQUITY

Particulars	As at March 31, 2022	As at March 31, 2021
Capital Reserve		
Securities Premium Account:		
General Reserve		
Investments in equity / MF through FVTPL		
Revenue arising from Interest free rental deposit		
Effective interest rate		
Deferred tax adjustment		
Reserve for equity instruments through other comprehensive income		
Actuarial movement through other comprehensive income (net of tax)		
Retained earnings (surplus in profit or loss account)	-7.48	-3.49
Total	-7.48	-3.49

(Handwritten signature)



NATURAL BIOGENEX PRIVATE LIMITED
Notes forming part of the Financial Statements

Note:

- i) Capital reserve: on account of forfeiture of amount paid on convertible shares warrants allotted to non promoters share
- ii) Securities Premium reserve: The amount received in excess of Face value of the equity shares is recognised as securities
- iii) General reserve: The reserve arises on transfer portion of the net profit pursuant to the earlier provisions of Companies Act, 1956. mandatory transfer to general reserve is not required under the Companies Act, 2013

Particulars	As at March 31, 2022	As at March 31, 2021
a) Retained Earnings		
Opening balance	-3.49	-
Profit/(Loss) for the year	-4.00	-3.49
Less: Transfer to Capital Redemption Reserve		-
Less: Dividend on Equity Shares		0
Less: Tax on Dividend on Equity Shares		
Less: Transfer to Reserves		
Less: IND AS Adjustment		
Closing Balance	-7.48	-3.49
The amount that can be distributed by the Company as dividends to its equity shareholders is determined based on the separate financial statements of the Company and also considering the requirements of the Companies Act, 2013. Thus, the amounts reported above are not distributable in entirety.		
Total Other Equity	-7.48	-3.49



NOTE 8

EQUITY SHARE CAPITAL

Particulars	As at March 2022	As at March 2021
AUTHORISED		
Equity Shares:		
1,00,00,000 Equity shares of Rs.10 each	1,000	1,000
ISSUED, SUBSCRIBED AND FULLY PAID UP		
10,000 Equity Shares of Rs 10/- each	1.00	1.00
Total	1.00	1.00

8.1 Reconciliation of number of shares and amount outstanding at the beginning and at the end of the reporting period.

Reconciliation	2021-22		2020-21	
	No.of shares	Amount in Rs	No.of shares	Amount in Rs
a) Equity Shares of Rs.10 each fully paid up				
At the beginning of the period	10,000	1,00,000	-	-
Issued during the period	-	-	10,000	1,00,000
At the end of the period	10,000	1,00,000	10,000	1,00,000
b) Redeemable Preference Share Capital (0%)				
At the end of the period				

8.2 Details of shares held by each shareholder holding more than 5 percent of equity shares in the Company:

Reconciliation	No. of shares held as at			
	March 31, 2022		March 31, 2021	
Natural Capsules Limited	10,000	100%	10,000	100%

8.3 Term attached to Equity Shares:

The Company has one class of equity share having a par value of Rs.10 per share. Each holder of equity share is entitled to one vote per share. The dividend when proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General meeting. Repayment of capital on liquidation will be in proportion to the number of equity shares held.

The Company has not issued any equity shares under ESOP (Employee Stock Option) .



NATURAL BIOGENEX PRIVATE LIMITED
Notes forming part of the Financial Statements

NOTE 10

NON-CURRENT BORROWINGS

Particulars	As at March 31, 2022	As at March 31, 2021
Unsecured - at amortised cost		
i) Bonds / Debentures		
Term Loans from Banks	1,950.12	
iii) Term Loans from others		
Other payable - Holding Company	2,002.14	917.48
Less : Current Maturities of Long term Debt	-	-
Grand Total	3,952.25	917.48

Repayment Terms: SBI-The loan is payable in 84 monthly instalments as follows: 24 Instalments of Rs.16,40,000 and 60 Instalments of Rs.33,44,000. **HDFC Bank-** The Loan is payable in 96 equal instalments of Rs.25,00,000/- each.

NOTE 10A

OTHER FINANCIAL LIABILITIES - NON CURRENT

Particulars	As at March 31, 2022	As at March 31, 2021
At Amortised Cost		
Advance from Customers		
Deposit/ Retention		
Total	-	-

NOTE 11

TRADE PAYABLES

Particulars	As at March 31, 2022	As at March 31, 2021
Dues of Micro Enterprises and Small Enterprises	-	-
Dues of creditors other than micro enterprises and small enterprises	-	-
Employee related	-	-
Total	-	-

Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	As at 31st March 2022
(i) MSME	-	-	-	-	-
(ii) Others	-	-	-	-	-
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
Total as at 31st March 2022	-	-	-	-	-

Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	As at 31st March 2021
(i) MSME	-	-	-	-	-
(ii) Others	-	-	-	-	-
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
Total as at 31st March 2021	-	-	-	-	-

Trade payables are non-interest bearing are normally settled between 30-60 days
The Company has requested its suppliers to confirm the status as to whether they are covered under the Micro, Small and Medium Enterprises Development Act, 2006. In the absence of confirmations from the suppliers, disclosure, if any, relating to unpaid amounts as at the year end together with interest paid / payable as required under the Act has not been given.

NOTE 12

OTHER FINANCIAL LIABILITIES - CURRENT

Particulars	As at March 31, 2022	As at March 31, 2021
At Amortised Cost		
a) Current maturities of long-term debt		
b) Other Liabilities		



Lease Rent Payable		
Payable for capital Goods Purchased	88.54	25.19
Other liabilities (refer Note below)	39.77	10.96
Total	128.31	36.15

NOTE

PROVISIONS -CURRENT

Particulars	As at March 31, 2022	As at March 31, 2021
a) Compensated absences (Earned Leave)		
b) Provision for gratuity		
c) Provision for Income Tax [net of TDS and Advance Tax]		
Total	-	-

NOTE 13

OTHER CURRENT LIABILITIES

Particulars	As at March 31, 2022	As at March 31, 2021
a) Statutory remittances (Contributions to PF, ESIC, TDS, GST, VAT, Service tax etc.)	7.15	4.88
b) Advances and Deposits from Customers / others	-	-
c) Related to expenses	0.75	0.21
Total	7.90	5.10



NATURAL BIOGENEX PRIVATE LIMITED
Notes forming part of the Financial Statements

NOTE 14

REVENUE FROM OPERATIONS

Particulars	Year Ended March 31, 2022	Year Ended March 31, 2021
(a) Sale of Products	-	-
(b) Other operating revenues	-	-
Total	-	-

NOTE 15

OTHER INCOME

Particulars	Year Ended March 31, 2022	Year Ended March 31, 2021
(a) Interest income		
On Bank Deposits	8.08	0.25
On other deposits		
(b) Dividend Income		
From equity investments designated		
(b) Other gains or losses		
- Profit on sale of Fixed Assets (net)		
- Net gain arising on financial assets designated		
- Net gain on foreign currency transaction		
(c) Other non-operating income		
Operating lease rental from Investment property		
Insurance claims received		
Liability no longer required written back		
Profit on sale of Investments		
Profit on sale of Assets		
Miscellaneous income		
Total	8.08	0.25

NOTE 16

Depreciation and amortisation expense

Particulars	Year Ended March 31, 2022	Year Ended March 31, 2021
Depreciation/amortisation on		
a) Property, Plant and Equipment	0	
b) Intangible Assets		
c) Right of use Asset - (Lease)		
Total	0	-

NOTE 17

OTHER EXPENSES

Particulars	Year Ended March 31, 2022	Year Ended March 31, 2021
Consumption of stores and spare parts		
Power and Fuel		
Rent		
Repairs and Maintenance -Buildings		
Repairs and Maintenance-Machinery		
Repairs and Maintenance -Others		
Bad Debts		
Insurance		
Exchange Rate Difference		
Rates and Taxes		
Freight & Clearing Expenses		
Bonus Paid		
Directors Sitting fees		
Auditor's Remuneration	1.00	0.25
Travelling Expenses - Foreign		
Travelling and Conveyance	7.29	3.20



[Handwritten signature]

NATURAL BIOGENEX PRIVATE LIMITED
Notes forming part of the Financial Statements

Professional Fees		
Commission		
Provision for Stock Loss		
Stock Lost on Fire		
CSR expenditure		
Security Charges		
Contract Labour Charges		
Postage and Courier		
Communication Expenses		
Business Promotion Expenses		
Research & Development Expenditure - Revenue in Nature		
Bank Charges		
Printing and Stationery		
Miscellaneous Expenses	3.58	0.28
Loss on Sale of Fixed Assets		
Total	11.87	3.73

PAYMENT TO AUDITORS

Particulars	Year Ended March 31, 2022	Year Ended March 31, 2021
a) Audit Fees	1.00	0.25
b) Fees for other services		
Total	1.00	0.25

Earnings Per Share

Particulars	Year Ended March 31, 2022	Year Ended March 31, 2021
Basic Earnings per share	-39.96	-34.85
Diluted Earnings per share	-39.96	-34.85

Basic Earnings per share

The earnings and weighted average number of equity shares used in the calculation of basic earnings per share as follow

Profit after Taxation	-4.00	-3.49
Earnings used in the calculation of basic earnings per share	-4.00	-3.49
Number of equity shares of 10 each outstanding at the beginning of the year	0.10	0.10
Number of equity shares of 10 each outstanding at the end of the year	0.10	0.10
Weighted Average number of Equity Shares	0.10	0.10

Diluted Earnings per share

The earnings and weighted average number of equity shares used in the calculation of diluted earnings per share as follows

Earnings used in the calculation of basic earnings per share	-4.00	-3.49
Adjustments (if any)	-	-
Earnings used in the calculation of diluted earnings per share	-4.00	-3.49

The weighted average number of equity shares for the purpose of diluted earnings per share reconciles to the weighted average number of equity shares used in the calculation of basic earnings per share as follows:

Weighted average number of equity shares used in calculation of basic earnings per share	0.10	0.10
Shares deemed to be issued for no consideration	-	-
Weighted average number of equity shares used in calculation of diluted earnings per share	0.10	0.10



NATURAL BIOGENEX PRIVATE LIMITED
Notes forming part of the Financial Statements

Note 18

Fair value of financial assets and financial liabilities that are not measured at fair value (but fair value disclosures are required)

Particulars	Fair value hierarchy	As at March 31, 2022		As at March 31, 2021	
		Carrying amount	Fair value	Carrying amount	Fair value
Financial Assets					
Financial assets at amortised cost:					
Trade receivables	Level 3	-	-	-	-
Cash and cash equivalents	Level 2	11.94	11.94	0.27	0.27
Bank balances other than cash and cash equivalents	Level 2	177.38	177.38	150.00	150.00
Other financial assets	Level 3	8.07	8.07	0.84	0.84

Particulars	Fair value hierarchy	As at March 31, 2022		As at March 31, 2021	
		Carrying amount	Fair value	Carrying amount	Fair value
Financial Liabilities					
Financial liabilities at amortised cost:					
Borrowings	Level 2	3,952	3,952	917	917
Trade payables	Level 3	-	-	-	-
Other financial liabilities	Level 3	128	128	36	36

Fair value hierarchy

The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable and consist of the following three levels:

- Level 1 — Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 — Inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3 — Inputs are not based on observable market data (unobservable inputs). Fair values are determined in whole or in part using a valuation model based on assumptions that are neither supported by prices from observable current market transactions in the same instrument nor are they based on available market data.

1. In case of trade receivables, cash and cash equivalents, trade payables, short term borrowings and other financial assets and liabilities it is assessed that the fair values approximate their carrying amounts largely due to the short-term maturities of these instruments

2. The fair values of the financial assets and financial liabilities included above have been determined in accordance with generally accepted pricing models based on a discounted cash flow analysis, with the most significant inputs being the discount rate that reflects the credit risk of counterparties.



1 Segment information

The Company's business comprises the Manufacture Of Chemicals And Chemical Products represents one business segment. Further, the Company has not yet commenced its commercial production.. Consequently, the disclosure of business and geographic segment- wise information is not applicable to the Company.

2 Capital management

For the purpose of the Company's capital management, capital includes issued capital, additional paid in capital and all other equity reserves attributable to the equity holders of the parent. The primary objective of the Company's capital management is to maximise the shareholder value.

In order to achieve this overall objective, the company's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans and borrowings. There have been no breaches in the financial covenants of any interest-bearing loans and borrowing in the current period.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The Company includes within net debt, interest bearing loans and borrowings, less cash.

Particulars	As at	As at
	31-Mar-22	31-Mar-21
Long term borrowings	1,950.12	-
Current maturities of long term borrowings	-	-
Short term borrowings	-	-
Less: Cash and cash equivalents	(12)	(0)
Less: Balances with Bank	(177)	(150)
Net debt	1,760.80	(150)
Equity	1.00	1
Other Equity	(7)	(3)
Total capital	(6.48)	(2)
Capital and net debt	1,754.32	(153)
Gearing ratio	100.37%	98.37%

20.1 Credit risk management

Credit risk refers to the risk that a counter party will default on its contractual obligations resulting in financial loss to the Company. The Company is exposed to credit risk from its operating activities (predominantly trade receivables) and from its financing activities, including deposits with banks and financial institutions, foreign exchange transactions and other financial instruments.

Customer credit risk is managed by each business unit subject to the Company's established policy, procedures and control relating to the customer credit risk management. The Company uses financial information and past experience to evaluate credit quality of majority of its customers and individual credit limits are defined in accordance with this assessment. Outstanding receivables and the credit worthiness of its counter parties are periodically monitored and taken up on case to case basis. There is no material expected credit loss based on the past experience. However, the Company assesses the impairment of trade receivables on case to case basis and has accordingly created loss allowance.

The credit risk on cash and bank balances is limited because the counter parties are banks with high credit ratings assigned by accredited rating agencies.

20.2 Liquidity risk management

The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities.

The table below provides details regarding contractual maturities of financial liabilities as at 31 March 2022

Particulars	Carrying amount	Less than 1 year	1-3 years	As at 31st March 2022
(i) MSME	-	-	-	-
(ii) Others	-	-	-	-
(iii) Disputed dues - MSME	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-
Total as at 31st March 2022	-	-	-	-

The table below provides details of financial assets at at 31st March 2022

Particulars	Carrying amount- 2021-22	Carrying amount- 2020-21
Trade receivables	-	-
Other Financial assets	-	-



[Handwritten signature]

NATURAL BIOGENEX PRIVATE LIMITED
Notes forming part of the Financial Statements

NOTE 21

Note (i) - Related Party Disclosures:

Related Party Transactions		
Description of Relationship :		
Key Management Personnel	Mr. Sunil Laxminarayana Mundra	Director
	Mr . Sushil Kumar mundra	Director
	NATURAL CAPSULES LIMITED	Holding Company
Details of Transactions	Amount in Rs.	
NATURAL CAPSULES LIMITED	2021-22	2020-2021
Purchase of Leasehold Land		351.80
Advance Received during the year	1,084.66	565.67
Allotment of Equity Shares	1.00	1.00
Balances outstanding at the end of the year		
Payables		
NATURAL CAPSULES LIMITED	2,002.14	917.48

NOTE 22 The company is not holding any benami property under the Benami Transactions (Prohibition) Act, 1988 and rules made there under.

NOTE 23 Quarterly returns or statements of current assets filed by the company with banks are in agreement with the books of accounts;

NOTE 24 The company is not declared wilful defaulter by any bank or financial institution or other lender during the year.

NOTE 25 The company has registered with the ROC on the charges created with in the time period as specified


NOTE 26 The company has not made any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956, during the year

NOTE 27 The company has not accepted any transaction not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 during the year.


NOTE 28 The company has not traded or invested in Crypto currency or Virtual currency during the financial year.

NOTE 29 Previous year figures have been regrouped to correspond to the current year classification where ever necessitated.

For P.Chandrasekar LLP
Chartered Accountants
FRN.: 000580S/S200066



Sunil L Mundra
Director
DIN:00214304


P Chandrasekar
Partner
Membership No.026037




Sushil Kumar Mundra
Director
DIN:214332

Place: Bengaluru
Date: 09/05/2022